Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02705677 · ClinicalTrials.gov registry record
Biobanking of Rett Syndrome and Related Disorders
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 752
- Enrollment target
NCT02705677: Completed study, sponsored by University of Alabama at Birmingham.
NCT02705677 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 752 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02705677 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 752 participants
- Enrollment target
Study Summary
The overarching purpose of this study is to advance understanding of the natural history of Rett syndrome (RTT), MECP2-duplication disorder (MECP2 Dup), RTT-related disorders including CDKL5, FOXG1, and individuals with MECP2 mutations who do not have RTT. Although all these disorders are the result of specific genetic changes, there remains broad clinical variation that is not entirely accounted for by known biological factors. Additionally, clinical investigators currently do not have any biomarkers of disease status, clinical severity, or responsiveness to therapeutic intervention. To address these issues, biological materials (DNA, RNA, plasma, cell lines) will be collected from affected individuals and in some cases from unaffected family members, initial evaluation performed to identify additional biological factors contributing to disease severity, and these materials will be stored for future characterization.
Primary Outcome
Characterize X-chromosome inactivation in RTT and correlate with clinical severity.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 752 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2021-07-31 |
What the finished NCT02705677 record still lists
NCT02705677 is an observational study that tracks outcomes without assigning an intervention. The registered 752 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02705677 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02705677 about?
NCT02705677 is a clinical study titled "Biobanking of Rett Syndrome and Related Disorders". The overarching purpose of this study is to advance understanding of the natural history of Rett syndrome (RTT), MECP2-duplication disorder (MECP2 Dup), RTT-related disorders including CDKL5, FOXG1, and individuals with MECP2 mutations who do not have RTT. Although all these disorders are the result...
What is the current status of trial NCT02705677?
This trial is currently completed. The enrollment target is 752 participants. The study started on 2017-09-01. Estimated completion is 2021-07-31.
Who is sponsoring clinical trial NCT02705677?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06559306 · 752 participants · Phase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- NCT05379985 · 754 participants · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT05427370 · 754 participants · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI